



EVIDENCE APPRAISAL WORKSHOP FOR PHILIPPINE HTA COUNCIL

Mission Report

List of Acronyms

DALY	Disability-Adjusted Life Year
DOH	Department of Health
DOST	Department of Science & Technology
FDA	Food and Drug Authority
HITAP	Health Intervention and Technology Assessment Program
HIU	HITAP International Unit
HTA	Health Technology Assessment
HTAC	HTA Council
ICER	Incremental Cost-Effectiveness Ratio
iDSI	International Decision Support Initiative
LMICs	Low- and Middle-Income Countries
NICE	National Institute of Health and Care Excellence
NUS	National University of Singapore
PhilHealth	Philippine Health Insurance Corporation
QALY	Quality-Adjusted Life Year
UHC	Universal Health Coverage
UN	United Nations

Table of Contents

Introduction.....	3
Workshop design.....	4
Summary of activities	4
Outcomes	9
Next Steps	12
Appendices.....	13
Appendix A – Agenda of activities	13
Appendix B – Questions asked in evaluation form	21
Appendix C – Workshop participants.....	22
Appendix D – High-level policy forum participants	35

Introduction

Health Technology Assessment (HTA) is a tool that seeks to help policymakers with challenges related to prioritization of interventions by offering evidence on which health technologies offer more ‘value-for-money’; i.e. those that lead to improvements in population health that are large relative to the cost involved.

In the Philippines, use of HTA is not completely new; there have been prior efforts to institutionalize a fair and systematic process of generating policy-relevant evidence to inform coverage of health services, such as listing of drugs in the national formulary and new benefits in the national social health insurance scheme. Previous laws and administrative issuances have served as basis for HTA activities in the past, but the passing of the Universal Health Coverage (UHC) Act ¹ in early 2019 has strengthened the legal framework for HTA policy and practice in the country and sparked increased interest in the topic. In accordance to the HTA provisions in the Act, an HTA Council (HTAC) has been established with several subcommittees. It is the first body of its kind tasked with facilitating provision of such evidence-informed financing and/or covering recommendations to the Department of Health (DOH) and PhilHealth, the latter being the manager of the national health insurance scheme. Additionally, it oversees and coordinates DOH’s and PhilHealth’s HTA processes, and reviews their existing benefits package. Aside from the HTAC, the law also institutionalizes a dedicated HTA office in the Department of Health, which will serve as a technical secretariat for HTAC and an evaluation team with evidence generation capacity.

In response to the World Health Organization’s request for proposal for a workshop to prepare HTAC members and key DOH and PhilHealth policymakers for their new roles under the UHC Act, the Health Intervention and Technology Assessment Program (HITAP) hosted a workshop and high-level policy forum on the use of HTA in the Philippines from 28-31 October 2019. HITAP is a semi-autonomous research unit in the Ministry of Public Health in Thailand and is a part of the International Decision Support Initiative (iDSI), a network of priority setting institutions from across the world. This workshop builds on an existing relationship between HITAP and the DOH; the two organizations have collaborated on HTA through various engagements since 2012.

This report summarizes the proceedings of the workshop and high-level meeting. It is structured as follows: description of the sessions, outcomes resulting from the workshop including feedback received, and the next steps identified.

¹ Republic of the Philippines, ‘RA No. 11223: An Act Instituting Universal Health Care for All Filipinos, Prescribing Reforms in the Health Care System, and Appropriating Funds’, 2019 <<https://www.officialgazette.gov.ph/downloads/2019/02feb/20190220-RA-11223-RRD.pdf>>.

Workshop design

For the HTAC to be successful in achieving its mandate, it is important that it possesses internal capacity and skills to appraise and synthesize evidence generated across different fields of expertise (i.e. clinical evidence, economics, and social science). Such expertise is required to fully and equally consider all evidence presented to it, increasing the quality of any evidence-informed recommendations that are made.

The workshop and high-level policy forum thus aimed to support the HTAC's capacity and to make the broader institutional setting more receptive to evidence-informed decision making. The activities were guided by HITAP's previous experiences conducting and institutionalizing HTA in the national public health sector of several countries, including Thailand, India, Indonesia and Singapore.

On 28-30 October 2019, an evidence appraisal workshop was held for which HTAC core- and sub-committee members, as well as selected PhilHealth policymakers, were invited. The workshop aimed to equip HTAC members with the skills required to successfully fulfil their mandates, and to familiarize PhilHealth policymakers with the HTA process. The workshop agenda can be found in Appendix A.

On 31 October 2019, a high-level policy forum was held, in which the Secretaries of the DOH and the Department of Science and Technology (DOST) and a parliamentarian joined participants from the preceding workshop as well as other stakeholders from the DOH and PhilHealth involved in the HTAC recommendation process. The forum aimed to make the broader institutional setting more receptive to increased use of evidence-informed decision making in health. The policy forum agenda can be found at the end of Appendix A.

Summary of activities

Technical aspects of HTA: approach, components and processes

Day 1 started with Dr. Wanrudee Isaranuwachai's presentation in which she introduced HTA and economic evaluations as a collaborative, multi-disciplinary process, the goal of which is not to decide, but to guide policy makers towards effectively being able to do so. Discussing costs as an important component of the HTA process, she discussed a three-step approach of conducting a costing exercise: identification of the perspective (hospital, societal, institutional etc.), measurement of the inputs and last, valuation of costs and benefits.

Ms. Waranya Rattanavipapong introduced technical concepts of comparative effectiveness research within HTA, by summarizing into three important questions:

1. Can the intervention work (efficacy)?
2. Does the intervention work (effectiveness)?
3. Is it worth it (valuation)?

Dr. Lam provided an overview of Quality Adjusted Life Years (QALYs), Disability Adjusted Life Years (DALYs) and measurement systems such as the EQ 5D and 15D, asking the pertinent question- ‘what is a representative sample of patients and how do we best capture those experiences?’



Figure 1: Dr. Yot Teerawattananon

Dr. Yot Teerawattananon built on previous presentations and explained the incremental cost-effectiveness ratio (ICER), emphasizing the difference between incremental and average calculations of costs and benefits. Focusing on economic modelling processes, he discussed the case of gastro-intestinal infections fueled by alcohol consumption in Northern Thailand, noting that Markov modelling allowed comparisons of transitions over time and repetitive incidents, as against more common decision-tree models (based on probabilities of single events happening in parallel).

Participants were given a chance to work on these topics with two group activities, one on an EQ-5D-5L exercise, and the other on developing a partially complete decision-tree model with input figures on costs and QALYs left empty for them to calculate. HITAP staff offered hands-on teaching assistance for both exercises, clarifying questions and offering guidance. The solutions for both activities were also provided.

Prof. Antony Culyer further detailed cost-effectiveness thresholds, offering an analogy of a bookshelf to explain HTA and budgets. Each book was representative of a health technology and a budget line drawn vertically through the shelf, determining which books (in this case, technology) could remain. He explained that all technologies could be effective, but just not effective enough given the budget constraint.

Dr. Teerawattananon followed this session with a presentation on conducting uncertainty analyses, starting off with the types of uncertainties: methodological, parametric, sampling, modelling, and generalizability. He also explained the use of a Monte Carlo simulation as an important type of analysis, which could account for simultaneous change in all parameters.



Figure 2: Critical appraisal by Alia Luz

Introducing critical appraisal, Ms. Alia Luz addressed all common quality issues found in economic evaluation studies, such as use of

surrogate end points, poor data quality and bias. Participants could use these learnings in an exercise reviewing a paper on PCV in the Philippines which Ms. Luz moderated.

Dr. Tessa Tan-Torres from the WHO offered insight into the social and ethical implications of the HTA, an important component of the process. She spoke of human rights, health access and an expanded tax base created from tobacco and alcohol taxes, suggesting that cost-effectiveness and HTA offered ethical policy levers as they provided the means and potential to gain maximum health for 99% of the population.

HTA experiences from around the world

Day 2 started with Prof. Culyer and Dr. Teerawattananon engaging the audience in a discussion on the value of HTA in both the United Kingdom and Thailand, elaborating on some judgements that have been made in the past, cases where price negotiations have come in handy as well as budgetary gains made to health systems from conducting simple economic evaluations, such as the case of Vietnam where the research pointed out that de-prioritizing some inefficient drugs from the national health package allowed extending coverage to an additional million people.



Figure 3: Prof. Culyer discussing HTA process

Prof. Culyer provided an extensive overview of the history and present-day functioning of NICE in England. Participants also watched and discussed a documentary titled “Price of Life”, which demonstrated the NICE decision-making process for Revlimid, a high-cost cancer drug in the United Kingdom.

Offering insight into the experiences of HTA from around the world, including UK, China and Thailand, the policy forum panel addressed these central themes:

- Findings from research showed that systems without HTA are likely to continue making reimbursement decisions until the budget runs out. On the other hand, systems with HTA tend to save health care budgets, without necessarily compromising on access to health technologies.
- High out of pocket expenditure and public hospital reform were the main drivers for establishing HTA in China. The country has made significant progress by developing process and method manuals for conducting multiple HTAs and establishing the National Centre of Medicine and Health Technology Assessment under the China National Health Development Research Center.
- HTA should involve patients in every step of HTA process, starting from topic selection to appraisal. This is the case in many countries including Thailand. In the UK, the public can witness NICE appraisal committee meetings.

- In some countries, FDA and HTA agency work together (complementary skills) to support the decision-making process. For example, Thai FDA serves as the secretariat for Subcommittee of National List of Essential Medicines. It is important to note that HTA does not substitute the FDA's role.
- Giving examples from Thailand's context, Dr. Yot explained that interventions cannot be included in a benefits package simply because they are cost-effective without understanding ethics and feasibility of implementation.

HTA in the Philippines

In the afternoon of Day 2, the Chair of the HTAC, Dr. Tolentino-Reyes, shared details on HTAC structure (core committee and sub-committees) and its mandate, as detailed in Section 34 of the Philippine UHC Act. She also spoke about how the Philippines must align with international regulatory standards on technologies and highlighted the need for members of HTAC and sub-committees to declare conflict of interest. Following this presentation, DOH and PhilHealth attendees extensively discussed the process for developing and implementing the HTA Methods Guide, tabled as the first activity of the HTAC, and the legal mandates of the Act. They also had questions on what a light touch HTA for the primary health package would need to be and if academics and universities would support HTAC with evidence generation and appraisal.




Figure 4: Dr. Tolentino-Reyes on the UHC Act

On Day 3, a practical exercise was offered as a means of tying together the previous teachings in the workshops. Three researchers from the Philippines presented their own HTA studies as cases, to the participants who divided themselves into groups; the exercise modelled a mock appraisal process. The groups began by electing members to be their Chair and note taker before the activity. Each Chair was expected to develop a consensus in their group and provide a recommendation on accepting, delaying/deferring or rejecting the intervention presented in each of the cases. Participants particularly appreciated the opportunity to practice appraisal discussions under expert supervision, and became increasingly aware of the need for a transparent and inclusive process in order to reach well-informed decisions.

The workshop concluded with a Q&A panel, where participants asked questions on availability of HTA at the provincial level, legal support that will be available to HTAC members as well as means to tackle political buy-in from governors and central administration as well as engagement with community advocacy groups.

The policy forum on the final day of the event saw participation of the Secretary and Undersecretary of DOH, Secretary of DOST, Congresswoman Angeline Helen Tan, President of PhilHealth and other esteemed members, all of whom showed great commitment to UHC and the use of HTA as a priority-setting mechanism. With DOST set to absorb HTAC in the next five years, there was also focus given from both departments to ensure a smooth transition. Discussions on the high burden of out of pocket payments in the Philippines and the interest in UHC as a mechanism to generate new opportunity, reduce inequality and an avenue to leave new Filipino behind dominated the purpose of the high-level meeting. Representatives from the Philippine Alliance of Patient Organization, National Institutes of Health and the Pharmaceutical and Healthcare Association of the Philippines, pledged their support to HTA, offering an open mindset towards learning, working with industry, and other support for HTAC members to fulfill their positional requirements.

HTAC’s planned activities during January and June 2020, were identified as follows:

- Finalizing HTA process and methods
- Revisiting existing prioritization tool
- Developing a prioritization tool for primary care technologies
- Developing a prioritization tool for existing PhilHealth packages
- Developing an ethical, legal, and social assessment tool for primary care technologies
- Developing assessment methods for particular technologies, e.g., traditional medicines, devices, complex interventions (e-health technologies)

Moving forward with HTA in the Philippines

In addressing many of questions and comments generated in the active discussions across the workshop period, these are the items of consideration for the Philippines as they move forward in implementing HTA:

- Need for caution when setting the ICER threshold, as it is hard to lower once defined. In the experience of NICE, they were generous because it was politically feasible, however the decision remains controversial.
- Thailand, like the Philippines, didn’t have a ready “bookshelf” of technologies, but started by kicking off the list all proven inefficient technologies. Over time, the benefits package grew to be more efficient.



Figure 5: Small-group discussions

- Importance of physical placement of HTAC, within or outside the Ministry and what this implied to all subsequent recommendations made.
- Practicing discernment in communicating final recommendations to the public and the need for HTAC to build its own credibility.

Outcomes

Participant evaluation form

At the end of the three-day workshop, all participants were invited to evaluate the activities through an online, anonymous, web form. The evaluation form probed participants' level of agreement with six statements and, in addition, asked for more general feedback through three open-ended questions. The full list of statements and questions posed can be found in Appendix B.

Overall, most participants provided their feedback through the online form; results were recorded for 47 out of 71 participants present on Day 3 (66% response rate). All participants submitted a response to the statement questions and the first open-ended question (questions 1-7), 37 participants provided suggestions (question 8), and 18 participants made use of the opportunity to provide additional comments (question 9).




Figure 6: Participant evaluation of activities

Questions 1-3 in general focus on the workshop aims, contents and delivery. The results show that 100% of respondents agreed that the aims and objectives of the workshop were clear and well defined, with 65% strongly agreeing (question 1). Regarding the preparation of workshop contents (question 2), 95% of respondents agreed it was well-prepared, with 83% strongly agreeing to this statement. A further 95% of respondents felt that the delivery of the workshop was conducive to their understanding of the topics discussed (question 3), with 78% strongly agreeing with this statement.

Questions 4-6 focused on how the workshop contributed to participants' understanding of HTA and whether they expect it will benefit their future work. 95% of participants felt that the workshop enhanced their knowledge about this topic (question 4), with only one respondent feeling neutral towards this statement. Another 95% felt that they have been able to identify avenues for future collaboration with likeminded individuals/organisations (question 5), although it must be noted that the percentage strongly agreeing (63%) is lower than for the other questions in this category. Lastly, 95% of respondents believe they will apply the knowledge gained from this event in their future activities (question 6).

Overall, questions 1-6 indicate that workshop participants were satisfied with the workshop. It is particularly promising to see such large percentages stating that the workshop enhanced their knowledge on HTA and that they will apply this knowledge in future activities.

As mentioned, questions 7-9 were open-ended and disseminating the feedback received in a single graph is therefore more challenging. Instead, we will focus on general themes identified in what participants liked most about the activities (question 7) and on suggestions for improvements (question 8). Each comment has been assigned to one or more theme(s), and themes which were found in at least three comments are presented below, together with their count.

Q7: “What did you like most about the event?”

Response theme:	Count:
Interactivity	20
Case studies	10
Theory	6
International experience	6

Q8: “Do you have any suggestions on how we could improve the event in the future?”

Response theme:	Count:
More time - case study	5
More time - discussions	5
Increase interactivity	4
Share materials beforehand	4

The results for question 7 and 8 show that participants particularly appreciated the level of interaction during the workshop; 20 participants mentioned this as one of the workshop’s strengths with another 4 participants stating they would like to see even more interaction in future events. The case study exercises on Day 3 were also rated highly – although five participants would have liked more time for each case.

The responses received for question 9 (“any other comments”) are of a general nature and are difficult to typify. In order to prevent the possible identification of respondents, these will not be discussed.

Video materials

The developments in the Philippines to achieve UHC and apply HTA through activities such as this workshop can guide other countries wishing to undertake similar efforts, and as such HITAP sought to document the activities. Therefore, and with permission of the DOH, two staff of HITAP’s in-house communication team attended the workshop and policy forum and recorded in each session. These recordings will be used to create online video material, which will be accessible freely, that will allow others to learn from the Philippine experience and for the Philippines to establish itself as HTA frontrunner.

Next Steps

As discussed earlier, HITAP has a history of supporting HTA efforts in the Philippines, and a guiding principle of the workshop was to ensure long-term capacity was built. It is expected that the lessons learned by stakeholders in the workshop will be useful to the institutionalization of HTA in the Philippines. Several participants will be present in the upcoming strategic planning workshop of the HTAC, in which the workshop activities will prove valuable.

In addition, it is expected that the case study exercises will be particularly valuable in the finalization process of the Philippines' HTA process & methods guidelines. Extensive discussions on the administrative issuance of a timeline of HTAC operations were held during the workshop. The strategic plan and finalization of the methods guideline, in particular, would feed into the development of the issuance of HTAC operations, which would provide the legal basis for how the HTAC should operate.

Lastly, HITAP together with the National University of Singapore (NUS) is hosting a separate HTA training workshop in the Philippines in January 2020. This workshop is on a registration basis, and can thereby be accessed by many more stakeholders. Information on the January 2020 workshop was shared with those present in the 28-30 October 2019 workshop; it will allow stakeholders that have strong interests in HTA to have a more in-depth training in conducting and assessing HTA research. All DOH and PhilHealth staff are eligible for reduced registration fees.



Figure 7: Workshop closing ceremony

Appendices

Appendix A – Agenda of activities

Dates: 28 – 31 October 2019

Location: Clark [28-30 Oct] & Manila [31 Oct]

Background:

The Philippine Universal Health Coverage (UHC) Act mandates that Health Technology Assessment (HTA) is institutionalized to ensure a fair and transparent mechanism for priority setting that will enable the Philippine Department of Health (DOH) and the Philippine Health Insurance Corporation (PhilHealth), two key agencies in the Philippine UHC system, make evidence-informed decisions for healthcare. The HTA Committee (HTAC) is the body tasked with facilitating provision of such evidence to inform financing and/or coverage decisions to the DOH and PhilHealth. Additionally, the HTAC is responsible for overseeing and coordinating the HTA processes for the DOH and PhilHealth, as well as reviewing their existing benefits packages.

For the HTAC to successfully fulfil its mandate, it is important that its members are able to appraise and synthesize evidence generated across different fields of expertise (i.e. clinical evidence, economics, and other social sciences). To this end, a four-day workshop is being conducted to equip the members of the HTAC with the skills required to consider the evidence presented to them, thereby increasing the quality of any evidence-informed recommendations made.

During the first three days, an appraisal training workshop will be held for members of the HTA core committee and subcommittee. They will be joined by representatives from PhilHealth and the Department of Science and Technology (DOST). Overarching goals of the sessions are to empower the HTA (sub-)committee members in technical and political aspects of HTA, and for participants to provide feedback on proposed HTA processes in the Philippines. There will be around 75 participants in total.

On day four, the participants from the previous days will be joined by DOH and (additional) PhilHealth policymakers involved in the HTA process for a sensitization workshop. The activities on this day aim to make the broader set of institutional partners more receptive to increased use of evidence-based decision making in health. There will be around 100 participants in total.

Time	Session	Description	Speaker(s)
DAY 1 Monday, 28 October 2019			
8:30 – 8:45	1. Welcome and Introductions	<ul style="list-style-type: none"> • Introductions & opening remarks • Objectives, overview of workshop, and schedule 	Prof. Anthony Culyer
8:45 – 9:15	2. Introduction to HTA & economic evaluation	<ul style="list-style-type: none"> • Introduction to HTA and its importance • Overview of economic evaluation methods 	Dr. Wanrudee Isaranuwachai
9:15 – 9:35	3. Costing interventions	<ul style="list-style-type: none"> • Different types of cost information • How to conduct costing studies, e.g. identification, measurement and valuation 	Dr. Wanrudee Isaranuwachai
9:35 – 10:10	4. Measuring clinical efficacy / effectiveness	<ul style="list-style-type: none"> • Measuring different type of health outcomes (surrogate vs. ultimate outcomes) • Identifying clinical effectiveness in economic evaluation • Overview of methods for evidence synthesis 	Ms. Waranya RattanaVIPapong
10:10 – 10:30	Coffee/tea break		
10:30 – 11:00	5. Measuring outcomes	<ul style="list-style-type: none"> • Concepts in measuring health utility (QALY) • Similarities & differences between DALY & QALY • Approaches for measuring health utility (VAS, TTO) • EQ-5D value set for the Philippines 	Dr. Hilton Lam
11:00 – 11:40	6. EQ-5D exercise (+ discussion)	<ul style="list-style-type: none"> • Measure utility in different health states using EQ-5D • Discuss exercise results 	Ms. Waranya RattanaVIPapong
11:40 – 12:00	7. Presenting CEA results and decision rule	<ul style="list-style-type: none"> • The Incremental Cost-Effectiveness Ratio (ICER) • Decision rules: league tables and threshold 	Dr. Yot Teerawattananon
12:00 – 13:00	Lunch		
13:00 – 13:15	8. Modelling	<ul style="list-style-type: none"> • Benefit of using models • Different types of modelling techniques incl. decision tree, Markov model & dynamic modelling 	Dr. Yot Teerawattananon
13:15 – 14:00	9. Modelling exercise (+ discussion)	<ul style="list-style-type: none"> • Create a basic HTA model • Discuss exercise results 	Mr. Sven Engels

Time	Session	Description	Speaker(s)
14:00 – 14:25	10. CE threshold	<ul style="list-style-type: none"> Understanding opportunity cost Decision rule and CE threshold 	Prof. Anthony Culyer
14:25 – 14:45	11. Uncertainty analysis	<ul style="list-style-type: none"> Tornado diagram in univariate or threshold analysis Probabilistic sensitivity analysis and cost-effectiveness acceptability curves (CEAC) 	Dr. Yot Teerawattananon
14:45 – 15:30	12. Critical appraisal of economic evidence	<ul style="list-style-type: none"> Research critique Model critique Common manipulations 	Ms. Alia Luz
15:30 – 16:15	13. Q&A	<ul style="list-style-type: none"> Open question & answer session on today's content 	Dr. Yot Teerawattananon
16:15 – 17:00	14. Social aspect of HTA	<ul style="list-style-type: none"> Principles of equity and social values in HTA Interactive Q&A 	Dr. Tessa Tan-Torres

Time	Session	Description	Speaker(s)
DAY 2			
Tuesday, 29 October 2019			
9:00 – 9:15	15. Welcome and recap	<ul style="list-style-type: none"> Recap of yesterday Today's schedule 	Ms. Alia Luz & Dr. Wanrudee Isaranuwatthai
9:15 – 10:00	16. Process & social value of HTA – case study UK	<ul style="list-style-type: none"> Discussion of HTA value added in UK Interactive Q&A 	Prof. Anthony Culyer
10:00 – 10:15	17. Introduction to BBC documentary	<ul style="list-style-type: none"> Introduce BBC Panorama documentary 'The Price of Life' https://vimeo.com/4796083 Introduce points of self-reflection for later discussion 	Dr. Yot Teerawattananon
10:15 – 11:15	18. Video documentary	<ul style="list-style-type: none"> Watch BBC Panorama documentary 'The Price of Life' 	
11:15 – 11:45	Coffee/tea break		
11:45 – 13:00	19. Interactive discussion on video	<ul style="list-style-type: none"> Discussion around technical concepts Discussion around policy aspects Interactive Q&A using Menti 	Prof. Anthony Culyer & Dr. Yot Teerawattananon
13:00 – 14:00	Lunch		

Time	Session	Description	Speaker(s)
14:00 – 15:30	20. Philippine HTA system	<ul style="list-style-type: none"> • Key HTA mandates • Roles & responsibilities of different stakeholders • Philippine HTA processes and methods 	Dr. Marita Tolentino-Reyes
15:30 – 16:30	21. Discussion	<ul style="list-style-type: none"> • Discussion on Philippine HTA system (methods & processes) • Interactive Q&A 	Dr. Marita Tolentino-Reyes Dr. Anna Melissa Guerrero

Time	Session	Description	Speaker(s)
DAY 3 Wednesday, 30 October 2019			
8:00 – 8:10	22. Welcome and recap	<ul style="list-style-type: none"> • Recap of yesterday & today's schedule 	Dr. Yot Teerawattananon
8:10 – 9:30	23. Philippine HTA case study 1: HIV	<ul style="list-style-type: none"> • Present real-world case study from the Philippines on HIV screening (15 mins) • Questions & Answers (10 mins) • Exercise: discuss recommendation in team (15 mins) • Exercise: share & justify recommendation (20 mins) • Presenter/expert response (10 mins) 	Mr. Geovin Dexter Uy All Within team Team chairpersons Mr. Geovin Dexter Uy
9:30 – 10:50	24. Philippine HTA case study 2: RRT	<ul style="list-style-type: none"> • Present real-world case study from the Philippines on renal replacement therapy (15 mins) • Questions & Answers (10 mins) • Exercise: discuss recommendation in team (15 mins) • Exercise: share & justify recommendation (20 mins) 	Ms. Dana Bayani All Within team Team chairpersons Ms. Dana Bayani

Time	Session	Description	Speaker(s)
		<ul style="list-style-type: none"> Presenter/expert response (10 mins) 	
10:50 – 12:10	25. Philippine HTA case study 3: HepC	<ul style="list-style-type: none"> Present real-world case study from the Philippines on Hepatitis C (15 mins) Questions & Answers (10 mins) Exercise: discuss recommendation in team (15 mins) Exercise: share & justify recommendation (20 mins) Presenter/expert response (10 mins) 	Dr. Hilton Lam All Within team Team chairpersons Dr. Hilton Lam
12:10 – 13:00	Lunch		
13:00 – 14:00	26. Interactive Q&A	<ul style="list-style-type: none"> Participants can propose and vote on questions through Menti, an interactive live feedback system Panel discusses most popular questions 	Panel: 1. Prof. Anthony Culyer 2. Dr. Yot Teerawattananon 3. Dr. Anna Melissa Guerrero 4. Dr. Marita Tolentino-Reyes 5. PhilHealth SVP Neri Santiago Moderator: Ms. Carmela Barcelona
14:00 – 14:15	27. Feedback on activities	<ul style="list-style-type: none"> Participants complete online pop quiz on HTA Survey on workshop experiences 	Mr. Sven Engels
14:15 – 14:30	28. Closing remarks	<ul style="list-style-type: none"> Overview of last three days Discuss plan for tomorrow 	Mr. Sven Engels
14:30 – 15:30	Coffee & networking		
15:30 – 19:00	Bus to Manila		

Time	Session	Description	Speaker(s)
DAY 4 Thursday, 31 October 2019			
9:00 – 9:30	A. Welcome and introductions	<ul style="list-style-type: none"> • Introductions • Welcoming remarks • Special message <ul style="list-style-type: none"> ○ Department of Health ○ PhilHealth ○ Department of Science and Technology (DOST) • Objectives and agenda 	<p>Dr. Denese De Guzman</p> <p>Rolando Enrique Domingo, MD, DPBO, DOH Chief of Staff / USec for Health Regulation</p> <p>Sec. Francisco T. Duque III, MD, MSc, DOH Secretary</p> <p>BGen. Ricardo C. Morales, AFP (ret.) FICD, PhilHealth President</p> <p>Sec. Fortunato Dela Peña, DOST Secretary</p> <p>Dr. Denese De Guzman</p>
9:30 – 10:30	B. Value of HTA – international experiences for local applications in the Philippines	<ul style="list-style-type: none"> • Short video on value of HTA (tinyurl.com/y5v6x89a) • Each panellist to give short presentation (8 mins) on their views on the value of HTA & how it applies to Philippine context using each other's country experience • Questions from audience using Menti 	<p>Panel:</p> <ol style="list-style-type: none"> 1. Prof. Anthony Culyer (U.K.) 2. Dr. Wanrudee Isaranuwatchai (Thailand) 3. Francis Ruiz (China) 4. Dr. Tessa Tan-Torres (WHO) <p>Moderator: Ms. Dana Bayani</p>
10:30 – 11:00	Coffee/tea break		

Time	Session	Description	Speaker(s)
11:00 – 12:00	C. Overview of HTAC	<ul style="list-style-type: none"> • The value of HTA in achieving the objectives of Universal Health Care • HTAC’s mandate and priorities • Questions from audience using Menti 	<p>Hon. Angeline “Helen” Tan, MD, Committee on Health Chair, Congress of the PHL</p> <p>Dr. Marita Tolentino-Reyes</p> <p>Dr. Yot Teerawattananon</p>
12:00 – 13:00	D. Panel discussion: How can PH stakeholders prepare themselves?	<ul style="list-style-type: none"> • Panel discussion on how stakeholders in the Philippine HTA system can prepare themselves and take the most advantage of the new HTA mechanism • Questions from audience using Menti 	<p>Panel:</p> <ol style="list-style-type: none"> 1. Dr. Israel Francis Pargas, PhilHealth 2. USec. Rolando Enrique Domingo, MD, DPBO, DOH-HTA Unit 3. Philippine Medical Association representative 4. Union of Local Authorities of the Philippines representative 5. University of the Philippines - National Institute of Health representative 6. Philippine Alliance of Patient Organizations representative 7. Pharmaceutical and Healthcare Association of the Philippines representative 8. Department of Science and Technology <p>Moderator: Dr. Anna Melissa Guerrero</p>

Time	Session	Description	Speaker(s)
13:00 – 13:15	E. Closing	<ul style="list-style-type: none"> Closing remarks 	Atty. Charade B. Mercado-Grande, Assistant Secretary of Health, Health Regulation Team
13:15 – 14:15	Lunch		

Reading list

Culyer AJ, Phōthisitā C, Santatiwongchai B. A star in the east: a short history of HITAP. Health Intervention and Technology Assessment Program; 2016.

Timmins N, Rawlins M, Appleby J. A terrible beauty: a short history of NICE. HITAP, 2016.

Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. Oxford university press; 2015 Sep 25.

Tantivess S, Teerawattananon Y, Mills A. Strengthening cost-effectiveness analysis in Thailand through the establishment of the health intervention and technology assessment program. Pharmacoeconomics. 2009 Nov 1;27(11):931-45.

Wilkinson T, Sculpher MJ, Claxton K, Revill P, Briggs A, Cairns JA, Teerawattananon Y, Asfaw E, Lopert R, Culyer AJ, Walker DG. The international decision support initiative reference case for economic evaluation: an aid to thought. Value in health. 2016 Dec 1;19(8):921-8.

Vassall A, Sweeney S, Kahn J, Gomez Guillen G, Bollinger L, Marseille E, Herzel B, DeCormier Plosky W, Cunnama L, Sinanovic E, Bautista-Arredondo S. Reference case for estimating the costs of global health services and interventions.

Adeagbo CU, Rattanavipapong W, Guinness L, Teerawattananon Y. The Development of the Guide to Economic Analysis and Research (GEAR) online resource for low-and middle-income countries' health economics practitioners: A commentary. Value in Health. 2018 May 1;21(5):569-72.

Jeffery M, Chi YL, Stewart M. iDSI Health Technology Assessment Toolkit. F1000Research. 2018 Sep 25;7.

Langer A. A framework for assessing Health Economic Evaluation (HEE) quality appraisal instruments. BMC health services research. 2012 Dec;12(1):253.

Appendix B – Questions asked in evaluation form

#	Question	Response options
1	The aims and objectives of the event were clear and well defined.	1) Strongly disagree 2) Disagree 3) Neutral 4) Agree 5) Strongly agree
2	The content of the event was well prepared.	
3	The delivery of the event was conducive to increasing my understanding of the topics discussed.	
4	This event enhanced my knowledge about the topic.	
5	I was able to identify avenues for future collaboration with likeminded individuals/organisations.	
6	I will apply the knowledge gained from this event in my future activities.	
7	What did you like most about the event?	Open (free-form text)
8	Do you have any suggestions on how we could improve the event in the future?	
9	Do you have any other comments?	

Appendix C – Workshop participants



Republic of the Philippines
PHILIPPINE HEALTH INSURANCE CORPORATION
 Citystate Centre, 709 Shaw Boulevard, Pasig City
 Call Center: (02) 441-7442 | Trunkline: (02) 441-7444
 www.philhealth.gov.ph



ATTENDANCE SHEET

**WORKSHOP ON THE REVIEW OF PHILHEALTH BENEFITS USING EVIDENCE APPRAISAL TO INFORM
 POLICY DECISIONS OF UNIVERSAL HEALTH CARE IMPLEMENTATION**
 October 27-30, 2019
 Quest Hotel, Clarkfield, Pampanga

	NAME	OFFICE/DEPARTMENT	SEX	SIGNATURE			
				Oct. 27, 2019	Oct. 28, 2019	Oct. 29, 2019	Oct. 30, 2019
1	Mr. Yot Teeraweharanon	HITAP	M				
2	Ms. Saudamini Vishwanath Dabak	HITAP	F				
3	Ms. Waranya Rattanavipapong	HITAP	F				
4	Ms. Warrudee Isaranuwatchai Ms. WARRUDEE	HITAP	F	W.I.	W.I	W.I	W.I
5	Mr. Sven Isar Engels	HITAP	M				
6	Mr. Benjarin Santatiwongchai	HITAP	M				
7	Ms. Diana Beatriz Samson Bayani	HITAP	F				
8	Ms. Alia Cynthia Gonzales Luz	HITAP	F				



PhilHealthofficial | teamphilhealth | actioncenter@philhealth.gov.ph



ATTENDANCE SHEET

**WORKSHOP ON THE REVIEW OF PHILHEALTH BENEFITS USING EVIDENCE APPRAISAL TO INFORM
 POLICY DECISIONS OF UNIVERSAL HEALTH CARE IMPLEMENTATION**

October 27-30, 2019

Quest Hotel, Clarkfield, Pampanga

	NAME	OFFICE/DEPARTMENT	SEX	SIGNATURE			
				Oct. 27, 2019	Oct. 28, 2019	Oct. 29, 2019	Oct. 30, 2019
1	Ms. Apinya Mattadet	HITAP	F				
2	Ms. Aparna Ananthakarishnan	HITAP	F				
3 +	Ms. Carmela Barcelona	WHO Representative in the Philippines	F				
4	Tessa Tan – Torres Edejer, MD	World Health Organization	F				
5	Dr. Joan Cristine Lareza	Department of Health	F				
6	Prof. Anthony Calyer	UK UK <i>think tank</i>	M				
7							
8							





ATTENDANCE SHEET

**WORKSHOP ON THE REVIEW OF PHILHEALTH BENEFITS USING EVIDENCE APPRAISAL TO INFORM
 POLICY DECISIONS OF UNIVERSAL HEALTH CARE IMPLEMENTATION**
October 27-30, 2019
Quest Hotel, Clarkfield, Pampanga

	NAME	OFFICE/DEPARTMENT	SEX	SIGNATURE			
				Oct. 27, 2019	Oct. 28, 2019	Oct. 29, 2019	Oct. 30, 2019
1	Dr. Anna Melissa Guerrero	DOH - HTAU	F				
2	Dr. Denese Cabigting-De Guzman		F				
3	Dr. Fides Maria Aileen V. Buenafe	DOH - HTAU	F				
4	Dr. Iris Conela Tagaro						
5	Dr. Janice Mandapat-Sanchez	DOH - HTAU	F				
6	Dr. Marvin Fajardo						
7	Ms. Sabrina Grace Aguinaldo	DOH HTAU	F				
8	Ms. Sarah May Obmaña	DOH HTAU	F				





ATTENDANCE SHEET

**WORKSHOP ON THE REVIEW OF PHILHEALTH BENEFITS USING EVIDENCE APPRAISAL TO INFORM
 POLICY DECISIONS OF UNIVERSAL HEALTH CARE IMPLEMENTATION**

October 27-30, 2019

Quest Hotel, Clarkfield, Pampanga

	NAME	OFFICE/DEPARTMENT	SEX	SIGNATURE			
				Oct. 27, 2019	Oct. 28, 2019	Oct. 29, 2019	Oct. 30, 2019
1	Ms. Sheena Jasley Samonte	DOH HTA Unit	F				
2	Ms. Jamaica Briones	DOH HTA unit	F				
3	Ms. Joyce Anne Ceria-Pereña	DOH - PD /HTA Unit	F				
4	Ms. Kate Dunlao	DOH PP /HTA	F				
5	Ms. Mica Anna Policarpio	DOH - HTAU	F				
6	Ms. Jovelyn Veranda	DOH - HTAU	F				
7	Mr. Yves Miel Zuñiga	DOH - HTAU	M				
8	Mr. Deinzal Uezono	DOH - HTAU	M				





ATTENDANCE SHEET

**WORKSHOP ON THE REVIEW OF PHILHEALTH BENEFITS USING EVIDENCE APPRAISAL TO INFORM
 POLICY DECISIONS OF UNIVERSAL HEALTH CARE IMPLEMENTATION**

October 27-30, 2019

Quest Hotel, Clarkfield, Pampanga

	NAME	OFFICE/DEPARTMENT	SEX	SIGNATURE			
				Oct. 27, 2019	Oct. 28, 2019	Oct. 29, 2019	Oct. 30, 2019
1	Mr. Arwin Jerome Onda	HTA Unit	M				
2	Mr. Patrick James Encarnacion	HTA Unit	M				
3	Ms. Anne Julienne Genuino	HTA unit	F				
4	Mr. Geovin Dexter Uy	HTA Unit	M				
5	Mr. Marvinson S. Fajardo	HTA unit	M				
6	Usec Rowena Buevarin, PhD	DOST	F				
7							
8							





ATTENDANCE SHEET

**WORKSHOP ON THE REVIEW OF PHILHEALTH BENEFITS USING EVIDENCE APPRAISAL TO INFORM
 POLICY DECISIONS OF UNIVERSAL HEALTH CARE IMPLEMENTATION**

October 27-30, 2019

Quest Hotel, Clarkfield, Pampanga

	NAME	OFFICE/DEPARTMENT	SEX	SIGNATURE			
				Oct. 27, 2019	Oct. 28, 2019	Oct. 29, 2019	Oct. 30, 2019
1	Dr. Jaime Montoya				<i>J</i>	<i>JMC</i>	
2	Dr. Noel Juban						
3	Dr. Isidro Sia		M	<i>IC Sia</i>	<i>IC Sia</i>	<i>IC Sia</i>	<i>IC Sia</i>
4	Prof. Luz Barbara Dones	<i>UP</i>	F	<i>Luz Dones</i>	<i>Luz Dones</i>	<i>Luz Dones</i>	<i>Luz Dones</i>
5	Dr. Annabelle Borromeo	<i>ATAC</i>	F	<i>Annabelle Borromeo</i>	<i>Annabelle Borromeo</i>	<i>Annabelle Borromeo</i>	<i>Annabelle Borromeo</i>
6	Dr. Mark Abaca	<i>DO ST</i>	M	<i>Mark Abaca</i>	<i>Mark Abaca</i>	<i>Mark Abaca</i>	<i>Mark Abaca</i>
7	Dr. Ma. Carmen Tolabing	<i>UP</i>	F	<i>Ma. Carmen Tolabing</i>	<i>Ma. Carmen Tolabing</i>	<i>Ma. Carmen Tolabing</i>	<i>Ma. Carmen Tolabing</i>
8	Mr. Vincent John H. Tumlos	<i>PCHRD</i>	M	<i>V. Tumlos</i>	<i>V. Tumlos</i>	<i>V. Tumlos</i>	<i>V. Tumlos</i>





ATTENDANCE SHEET

**WORKSHOP ON THE REVIEW OF PHILHEALTH BENEFITS USING EVIDENCE APPRAISAL TO INFORM
 POLICY DECISIONS OF UNIVERSAL HEALTH CARE IMPLEMENTATION**

October 27-30, 2019

Quest Hotel, Clarkfield, Pampanga

	NAME	OFFICE/DEPARTMENT	SEX	SIGNATURE			
				Oct. 27, 2019	Oct. 28, 2019	Oct. 29, 2019	Oct. 30, 2019
1	Dr. Minerva Calimag						
2	Ms. Agnette Peralta	UST	F				
3	Dr. Maria Carinnes A. ^{Lejandrino} Gonzales	UST	F				
4	Dr. Imelda Pena	UPMLA	F				
5	Dr. Sheriah Laine M. de Paz	POST	F				
6	Dr. Pia Regina Fatima C. Zamora	POST	F				
7	Dr. Marita V. Reyes	NEC	F				
8	Dr. Martha Cayad - an	HTAC	F				





ATTENDANCE SHEET

**WORKSHOP ON THE REVIEW OF PHILHEALTH BENEFITS USING EVIDENCE APPRAISAL TO INFORM
 POLICY DECISIONS OF UNIVERSAL HEALTH CARE IMPLEMENTATION**

October 27-30, 2019

Quest Hotel, Clarkfield, Pampanga

	NAME	OFFICE/DEPARTMENT	SEX	SIGNATURE			
				Oct. 27, 2019	Oct. 28, 2019	Oct. 29, 2019	Oct. 30, 2019
1	Prof. Catherine Lee Ramos	DLSM / MEM	F				
2	Prof. Maria Isabelita Rogado	AU/GSN	F				
3	Dr. Mediadora Saniel	SNV COUNCIL / AHRD	F				
4	Dr. Cecilia Maramba – Lazarte	HTAC	F				
5	Dr. Mary Anne Castor	UP - Manila	F				
6	Dr. Jose Enrico Lazaro	UP Diliman	M				
7	Dr. Martin Camara	PITAC	M				
8	Dr. Limuel Abrogena	PAPP	M				





ATTENDANCE SHEET

**WORKSHOP ON THE REVIEW OF PHILHEALTH BENEFITS USING EVIDENCE APPRAISAL TO INFORM
 POLICY DECISIONS OF UNIVERSAL HEALTH CARE IMPLEMENTATION**
October 27-30, 2019
Quest Hotel, Clarkfield, Pampanga

	NAME	OFFICE/DEPARTMENT	SEX	SIGNATURE			
				Oct. 27, 2019	Oct. 28, 2019	Oct. 29, 2019	Oct. 30, 2019
1	Dr. Marc James Delos Santos	HTAC	M				
2	Dr. Iris Thiele Isip - Tan	UP college of medicine	F				
3	Dr. Katherine Ann Reyes	UP College of Public Health	F				
4	Dr. Aleli Kraft	UP School of Law	F				
5	Dr. Hilton Lam	HTADS OPM	M				
6	Jacinto Blos V. Mantang III	UPCM - DEPT. OF CLINICAL EPI	M				
7	Pro Rode Roman R.	DOST-CC (STRAT)	M				
8	Ru C CASTRO	HTAC - Core	M				





Republic of the Philippines
PHILIPPINE HEALTH INSURANCE CORPORATION
 Citystate Centre, 709 Shaw Boulevard, Pasig City
 Call Center: (02) 441-7442 | Trunkline: (02) 441-7444
 www.philhealth.gov.ph



ATTENDANCE SHEET

**WORKSHOP ON THE REVIEW OF PHILHEALTH BENEFITS USING EVIDENCE APPRAISAL TO INFORM
 POLICY DECISIONS OF UNIVERSAL HEALTH CARE IMPLEMENTATION**
October 27-30, 2019
Quest Hotel, Clarkfield, Pampanga

	NAME	OFFICE/DEPARTMENT	SEX	SIGNATURE			
				Oct. 27, 2019	Oct. 28, 2019	Oct. 29, 2019	Oct. 30, 2019
1	Dr. Madeline Valera		F				
2							
3							
4							
5							
6							
7							
8							



PhilHealthofficial | teamphilhealth | actioncenter@philhealth.gov.ph



Republic of the Philippines
PHILIPPINE HEALTH INSURANCE CORPORATION

Citystate Centre, 709 Shaw Boulevard, Pasig City
 Call Center: (02) 441-7442 | Trunkline: (02) 441-7444
 www.philhealth.gov.ph



PhilHealth
 Tungo sa Kalusugan
 Para sa Lahat

ATTENDANCE SHEET

**WORKSHOP ON THE REVIEW OF PHILHEALTH BENEFITS USING EVIDENCE APPRAISAL TO INFORM
 POLICY DECISIONS OF UNIVERSAL HEALTH CARE IMPLEMENTATION**

October 27-30, 2019

Quest Hotel, Clarkfield, Pampanga

	NAME	OFFICE/DEPARTMENT	SEX	SIGNATURE			
				Oct. 27, 2019	Oct. 28, 2019	Oct. 29, 2019	Oct. 30, 2019
1	ASVP Nerissa Santiago	Actuarial and Risk Management Sector	F	<i>Nerissa</i>	<i>Nerissa</i>	<i>Nerissa</i>	<i>Nerissa</i>
2	SM Atty. Rogelio A. Pocallan Jr.	Internal Legal Department	M				
3	ASM Mel C. Santillan, MD	Benefits Development and Research Department	F	<i>Mel</i>	<i>Mel</i>	<i>Mel</i>	<i>Mel</i>
4	Gilberto de Guzman, MD	Health Finance Policy Sector	M	<i>Gilberto</i>	<i>Gilberto</i>	<i>Gilberto</i>	<i>Gilberto</i>
5	Rodley Desmond Daniel Carza	Office of the Chair	M	<i>Rodley</i>	<i>Rodley</i>	<i>Rodley</i>	<i>Rodley</i>
6	Helena Ruby Hernandez	Corporate Planning Dept.	F	<i>Helena</i>	<i>Helena</i>	<i>Helena</i>	<i>Helena</i>
7	Glenda Ortaliz	Office of the Actuary	F	<i>Glenda</i>	<i>Glenda</i>	<i>Glenda</i>	<i>Glenda</i>
8	Raymond Castillo	Standards and Monitoring Department	M	<i>Raymond</i>	<i>Raymond</i>	<i>Raymond</i>	<i>Raymond</i>



PhilHealthofficial | teamphilhealth | actioncenter@philhealth.gov.ph



ATTENDANCE SHEET

**WORKSHOP ON THE REVIEW OF PHILHEALTH BENEFITS USING EVIDENCE APPRAISAL TO INFORM
 POLICY DECISIONS OF UNIVERSAL HEALTH CARE IMPLEMENTATION**
October 27-30, 2019
Quest Hotel, Clarkfield, Pampanga

	NAME	OFFICE/DEPARTMENT	SEX	SIGNATURE			
				Oct. 27, 2019	Oct. 28, 2019	Oct. 29, 2019	Oct. 30, 2019
1	Marvin C. Galvez, MD	Benefits Development and Research Department	M				
2	Adeline A. Mesina, MD	Benefits Development and Research Department	F				
3	Merla Rose D. Reyes, RPh	Benefits Development and Research Department	F				
4	Abigail R. Estrada, RN	Benefits Development and Research Department	F				
5	Michael F. Dizon, PTRP	Benefits Development and Research Department	M				
6	Gemma S. Vecina	Benefits Development and Research Department	F				
7	Daryl Ruviro C. Calabio	Benefits Development and Research Department	M				
8	Glenn I. David, RN	Benefits Development and Research Department	M				





ATTENDANCE SHEET

**WORKSHOP ON THE REVIEW OF PHILHEALTH BENEFITS USING EVIDENCE APPRAISAL TO INFORM
 POLICY DECISIONS OF UNIVERSAL HEALTH CARE IMPLEMENTATION**









October 27-30, 2019

Quest Hotel, Clarkfield, Pampanga

	NAME	OFFICE/DEPARTMENT	SEX	SIGNATURE			
				Oct. 27, 2019	Oct. 28, 2019	Oct. 29, 2019	Oct. 30, 2019
1	Laurence Sabido, MD	Office of the Area Vice President for Area IV	M				
2	Dante B. Domingo	Benefits Development and Research Department	M				
3	Eugenio Padilla Jr.	Corporate Communication Dept.	M				
4	Jose Marie San Vicente	Corporate Communication Dept.	w				
5	Jonathan G. Babilon	PRMO - Motorpool	m				
6	Rene Fariolan	PRMO - Motorpool	M				
7	ASM Cherie Carmen B. Divina	Comptrollership Department-FMS	F				
8							



Appendix D – High-level policy forum participants

 Republic of the Philippines Department of Health Kagawaran ng Kalusugan ISO 9001:2008 CERTIFIED					
ACTIVITY:	High Level Forum on the Role of Health Technology Assessment (HTA) for Universal Health Care			VENUE:	The Sulu Riviera
FACILITATOR:	Health Technology Assessment (HTA)			DATE:	October 31, 2019
NAME	OFFICE	DESIGNATION	EMAIL ADDRESS	CONTACT NO.	SIGNATURE
A. Department of Health - Central Office					
1	Usec. Myrna C. Cabotaje	Public Health Service Team	Undersecretary of Health		
2	Usec. Rolando Enrique D. Domingo	Office of the Chief of Staff and Health Regulation Team	Undersecretary of Health		
3	Usec. Roger P. Tong-An	Administration and Financial Management Team	Undersecretary of Health		
4	Asec. Abdullah B. Dumama, Jr.	Field Implementation and Coordination Team (Visayas and Mindanao)	Assitant Secretary of Health		
5	Dr. Azucena M. Dayanghirang	National Nutrition Council (NNC)	Executive Director		
6	Dr. Fides Maria Aileen Buenafe	Health Regulation Team	Executive Assistant		
7	Dr. Janice Mandapat-Sanchez	Health Regulation Team	Medical Officer III		
8	Dr. Irish Conela Tagaro	Health Regulation Team	Medical Officer III		
9	Dir. Ariel Valencia	Supply Chain Management Officer	Director IV		
19	Dr. Napoleon L. Arevalo	Disease Prevention and Control Bureau (DPCB)	OIC- Director IV		
20	Dr. Rosalie Paje	Lifestyle-Related Disease	Division Chief, MO V		
21	Dr. Clarito Cairo, Jr.	Cancer/Thyroid	Medical Officer IV		
22	Dr. Fatima C. De Guzman	Tobacco/CRD/Alcohol	Medical Officer IV		



Department of Health

Kagawaran ng Kalusugan
ISO 9001:2008 CERTIFIED

ACTIVITY:	High Level Forum on the Role of Health Technology Assessment (HTA) for Universal Health Care	VENUE:	The Sulu Riviera
FACILITATOR:	Health Technology Assessment (HTA)	DATE:	October 31, 2019

	NAME	OFFICE	DESIGNATION	EMAIL ADDRESS	CONTACT NO.	SIGNATURE
23	Dr. Carmela N. Granada	HPN/DM	Medical Officer IV			
24	Dr. Ronaldo Quintana	Rabies Program	Medical Officer IV			
25	Mr. Aldrin Q. Reyes	IDPCD	Supervising Health Program Officer			
26	Ms. Liezl A. Fernandez	IDED	Senior Health Program Officer			
27	Dr. Norilyn Evangelista	Dengue Program	Medical Officer IV			
28	Ms. Onofria C. De Guzman	Family Planning	Senior Health Program Officer			
29	Dr. Gemma Arellano	ERDLD Program	Medical Specialist IV			
30	Ms. Marlene Galvan	LRDD	Nurse IV			
31	Ms. Frances Prescilla Cuevas	ENCD	OIC-Divisio Chief			
32	Dr. Maria Rosario Sylvia Uy	ENCD	Medical Officer IV			
33	Ms. Maria Cristina Reymundo	ENCD	Senior Health Program Officer			
34	Dr. Ruby Contantino	Disease Prevention and Control Bureau	Director IV			
35	Dr. Ma. Elizabeth Caluag	Occupational Disease	Division Chief			
36	Dr. Valeriano Timbang, Jr.	ODD	Medical Officer IV			



Department of Health

Kagawaran ng Kalusugan
ISO 9001:2008 CERTIFIED

ACTIVITY:	High Level Forum on the Role of Health Technology Assessment (HTA) for Universal Health Care	VENUE:	The Sulu Riviera
FACILITATOR:	Health Technology Assessment (HTA)	DATE:	October 31, 2019

	NAME	OFFICE	DESIGNATION	EMAIL ADDRESS	CONTACT NO.	SIGNATURE
37	Engr. Rens Timbang	ODD	Senior Health Program Officer			
38	Dr. Franklin C. Diza	Infectious Diseases for Provention and Control	Division Chief and Program Manager			
39	Dr. Leda M. Hernandez	Infectious Diseases Elimination Control	Division Chief and Program Manager			
40	Dr. Rosalind G. Vianzon	Environmental Related Disease	Division Chief and Program Manager			
41	Dr. Anthony Calibo	Children's Health Development	Division Chief and Program Manager			
42	Dr. Cherylle G. Gavino	Womens and Men's Health Development	Division Chief and Program Manager			
43	Dr. Ma. Theresa G. Vera	Health Facilities Development Bureau	Director IV			
44		National Immunization Committee				
45		National Immunization Committee				
46		Family Health Office				
47	Ms. Roda S. Pascua	Food and Drug Administration	Engr. Rens III			
48	Mr. Armando B. Dumindin	FDA	Engr. III			
49		FDA				
50	Ms. Crispinita A. Valdez	Procurement Service	Director IV			



ACTIVITY:	High Level Forum on the Role of Health Technology Assessment (HTA) for Universal Health Care	VENUE:	The Sulu Riviera
FACILITATOR:	Health Technology Assessment (HTA)	DATE:	October 31, 2019

	NAME	OFFICE	DESIGNATION	EMAIL ADDRESS	CONTACT NO.	SIGNATURE
51		Procurement Service				
52	Dir. Mylene M. Beltran	Health Policy and Development Bureau (HPDPB)	Director IV	[REDACTED]		
53	Dr. Gloria Nenita Velasco	HPDPB	MD IV			
54	Dr. Annabelle Pabio-De Guzman	Philippine Traditional and Alternative Healthcare (PTAHC)				
55	Atty. Carmencita D. Castro-Santos	PITACH				
56	Ms. Lilibeth C. Delos Reyes	PITACH				
57	Dr. Anna Melissa S. Guerrero	Pharmaceutical Division/ Health Technology Assessment Unit (HTAU)	Chief and Head			
58	Ms. Joyce Anne Ceria-Pereña	PD/HTAU	Pharmacist V			
59	Ms. Anne Jullienne Genuino	PD/HTAU	Senior Health Program Officer			
60	Ms. Kate Dunlao	PD/HTAU	Pharmacist II			
61	Mr. Geovin Dester Uy	Health Technology Assessment (HTA)	Pharmacist III			
61	Ms. Sabrina Aguinaldo	HTAU	Pharmacist II			
62	Ms. Sarah Obmana	HTAU	Pharmacist II			
63	Mr. Patrick James Encarnacion	HTAU	Pharmacist II			
64	Mr. Arwin Jerome Onda	HTAU	Pharmacist II			
65	Ms. Sheena Samonte	HTAU	Health Program Officer II Pharmacist II			



ACTIVITY:	High Level Forum on the Role of Health Technology Assessment (HTA) for Universal Health Care	VENUE:	The Sulu Riviera
FACILITATOR:	Health Technology Assessment (HTA)	DATE:	October 31, 2019

	NAME	OFFICE	DESIGNATION	EMAIL ADDRESS	CONTACT NO.	SIGNATURE
66	Ms. Mica Policarpio	HTAU				
67	Mr. Yves Miel Zuñiga	HTAU				
68	Mr. Donato Dennis	DOH-MRU Central Officer				
69	Mr. Romeo Caparras	DOH-MRU Central Officer				
70	Ms. Evelyn Dioso	DOH-MRU Central Officer				
71	Dr. Madeleine de Rosas-Valera					
72	CONCEPCION LIBERAN	DOH PS				
73	ANTONIO RAMON PATERNIO	DOH ACS				
74	Engr. Teodoro Battad	FDA-DOH				
75	Jasmina Mendiola	FDA-CDAR				
76	Meah Pacheco	FDA-CDAR				
77	JERRY ARANCES	DOH - OSEC				
78	MICHELLE BALAGUER	DOH - OSEC				
79	Jose Rosefel Paghasiam					
80	MICHAEL VERGARA	DOH - OSEC				
81	Angel Leon Espineta II	DOH - HPSDT				
82	Paulo Cabrera	DOH FICT - Luzon				
83	Karen Anzor	HDR				



ACTIVITY:	High Level Forum on the Role of Health Technology Assessment (HTA) for Universal Health Care	VENUE:	The Sulu Riviera
FACILITATOR:	Health Technology Assessment (HTA)	DATE:	October 31, 2019

	NAME	OFFICE	DESIGNATION	EMAIL ADDRESS	CONTACT NO.	SIGNATURE
84	Lorra Sayre	OSAC	LD			
85	ETWAL CARON T	OPCES	EA			
86	Daniel Uyong	HTAU	SEKPO			
87	SARAH MAY OBIWATA	HTAU	PHARMACEUTIST			
88	Marvin S. Payada	HTAU	MOB			
89	Imelda Bionis	HTAU	WHPO			
90						
91						
92						
93						
94						
95						
96						
97						
98						
99						
100						













ACTIVITY:	High Level Forum on the Role of Health Technology Assessment (HTA) for Universal Health Care	VENUE:	The Sulu Riviera, Quezon City
FACILITATOR:	Health Technology Assessment (HTA)	DATE:	October 31, 2019

	NAME	OFFICE	DESIGNATION	EMAIL ADDRESS	CONTACT NO.	SIGNATURE
B. Philippine Health Insurance Corporation (PHIC)						
1	Mr. Rolando Josecito D. Bautista	PHIC	Philhealth Board Member			
2	Mr. Carlos G. Dominguez III	PHIC	Philhealth Board Member			
3	Atty. Wendel E. Avisado	PHIC	Philhealth Board Member			
4	Mr. Alejandro L. Cabading, CPA	PHIC	Philhealth Board Member			
5	Atty. Federico V. Abuan, Jr.	PHIC	Philhealth Board Member			
6	Ms. Ma. Sharon P. Almanza	PHIC	Philhealth Board Member			
7	Ms. Tina Rose Marie L. Canda	PHIC	Philhealth Board Member			
8	Ms. Rosalia V. De Leon	PHIC	Philhealth Board Member			
9	Ms. Maria S. Gopalan	PHIC	Philhealth Board Member			
10	Mr. Javier Jimenex	PHIC	Philhealth Board Member			
11	Atty. Ryan S. Lita	PHIC	Philhealth Board Member			
12	Ms. Camencita P. Mahinay	PHIC	Philhealth Board Member			
13	Atty. Jacinto V. Paras	PHIC	Philhealth Board Member			
14	Dr. Israel Francis A. Pargas	PHIC	Senior Vice President, Health Finance Policy Sector			
15	Ms. Jovita V. Aragona	PHIC	Senior Vice President/ Chief Information Officer, Information Management Sector			



ACTIVITY:		High Level Forum on the Role of Health Technology Assessment (HTA) for Universal Health Care			VENUE:	The Sulu Riviera, Quezon City
FACILITATOR:		Health Technology Assessment (HTA)			DATE:	October 31, 2019
	NAME	OFFICE	DESIGNATION	EMAIL ADDRESS	CONTACT NO.	SIGNATURE
16	Mr. Dennis S. Mas	PHIC	Senior Vice President Management Services Sector			
17	Mr. Renato L. Linsiac, Jr.	PHIC	Senior Vice President Fund Management Sector			
18	Atty. Jonathan P. Mangaoang	PHIC	Corporate Secretary			
19	Dr. Shirley B. Domingo	PHIC	Vice President Corporate Affairs Group			
20	Dr. Francisco Z. Soria	PHIC	Vice President Member Management Group			
21	Ms. Ann Marie C. San Andres	PHIC	Chief Audit Executive / OIC-VP, Internal Audit Group			
22	Mr. Oscar B. Abadu, Jr.	PHIC	Vice President Quality Assurance Group			
23	Mr. Michael Jibson C. Hernandez	PHIC	Acting Senior Manager			
24	Dr. Clementine A. Baurista	PHIC	Area Vice President, Area IV			
25	Ms. Nerrisa Santiago	PHIC	Acting Senior Vice President, Actuarial and Risk Management Sector			
26	Ms. Evangeline F. Racelis	PHIC	Senior Manager, Social Health Insurance Academy			
27	Atty. Recto M. Pantí	PHIC	Acting Senior Manager, International and Local Engagement Department			
28	Ms. Josephine P. Niwane	PHIC	BM, Representing DSWD as Alternate BM			
29	Atty. Rogelio A. Pocallan, Jr.	PHIC	Senior Manager Internal Legal Department			

ACTIVITY:		High Level Forum on the Role of Health Technology Assessment (HTA) for Universal Health Care			VENUE:	The Sulu Riviera, Quezon City
FACILITATOR:		Health Technology Assessment (HTA)			DATE:	October 31, 2019
	NAME	OFFICE	DESIGNATION	EMAIL ADDRESS	CONTACT NO.	SIGNATURE
30	Dr. Mel C. Santillan	PHIC	Acting Senior Manager, Benefits Development and Research Department (BDRD)			
31	Dr. Lamber David	PHIC	Acting Senior Manager Standards and Monitoring Dept.			
32	Dr. Kim P. Gariando	PHIC	OIC-Division Chief Office of the Corporate Secretary			
33	Dr. Gilbert De Guzman	PHIC	Medical Specialists III Health Finance Policy Sector			
34	Dr. Marvin C. Galvez	PHIC	OIC-Division Chief, BDRD			
35	Dr. Adeline C. Mesina	PHIC	Medical Specialist III, BDRD			
36	Ms. Abigail R. Estrada	PHIC	Chief Social Insurance Specialist Inpatient Benefits Team, BDRD			
37	Ms. Merla Rose D. Reyes	PHIC	Chief Social Insurance Specialist, Product Team for Special Benefit, BDRD			
38	Mr. Michael F. Dizon	PHIC	Social Insurance Specialist Product Team for Special Benefits			
39	Ms. Gemma S. Vecina	PHIC	Social Insurance Analyst Product Team for Special Benefits			
40	Mr. Daryl C. Calabio	PHIC	Social Insurance Assistanc I Product Team for Special Benefits			
41	Mr. Glenn David	PHIC	Social Insurance Assistanc I Product Team for Special Benefits (BDRD)			
42	Ms. Glenda Ortaliz	PHIC	Acting Actuarial Associate Office of the Actuary			
43		PHIC	Office of the President			

ACTIVITY:	High Level Forum on the Role of Health Technology Assessment (HTA) for Universal Health Care	VENUE:	The Sulu Riviera, Quezon City
FACILITATOR:	Health Technology Assessment (HTA)	DATE:	October 31, 2019

	NAME	OFFICE	DESIGNATION	EMAIL ADDRESS	CONTACT NO.	SIGNATURE
44	CHEMF DIVILA	PHIC	Fund Management Sector			
45	Bernadette C. Lico MD	PHIC	Corporate Planning Department			
46		PHIC	Internal Audit Group			
47		PHIC	Legal Sector			
48		PHIC	Office of the Health Finance Policy Sector			
49	ENGELIO D. PABICHA	PHIC	Corcom			
50	Christine C. Bayot	PHIC	Supervising And. Sup. Lper.			
51	Etrabal Laberte	PHIC	Head Executive Asst.			
52	Raymond Castillo	PHIC	GMD			
53	Don Marie Sanvicente	PHIC	Corcom			
54	Pamela Marie C. Pascua	DSWD	Executive Assistant III			
55	Klean Ruby A. Hermans	PHIC	Mag. Officer III			
56	Melchior Ambay	PHIC	PRID			
57	Loreto Rey Z. Cabatay	DO	PRID			
58	Amson A. Palaran	II	II			
59	Amy Mariam Masahud	PHIC	HES			
60	ROBERTO MERCADO JR	PHIC	HFTS			
61	HERNAN G. CALUNA	PHIC	HFTS			
62						








ACTIVITY:	High Level Forum on the Role of Health Technology Assessment (HTA) for Universal Health Care	VENUE:	The Sulu Riviera
FACILITATOR:	Health Technology Assessment (HTA)	DATE:	October 31, 2019

	OFFICE	DESIGNATION	EMAIL ADDRESS	CONTACT NO.	SIGNATURE
E. DOH Executive Committee					
1	Hon. Francisco T. Duque	Office of the Secretary	Secretary		
2	Usec. Mario C. Villaverde	Health Policy and Systems Development Team	Undersecretary of Health		
3	Usec. Ma. Carolina Vidal-Taiño	Procurement and Supply Chain Management Team	Undersecretary of Health		
4	Dr. Gerardo V. Bayugo	Field Implementation and Coordination Team	Undersecretary of Health		
5	Usec. Lilibeth C. David	Health Facilities and Infrastructure Development Team	Undersecretary of Health		
6	Asec. Charade B. Mercado-Grande	Office of the Chief of Staff and Health Regulation Team	Assitant Secretary of Health		
7	Asec. Maria Rosario S. Vergeire	Public Health Service Team	Assitant Secretary of Health		
8	Asec. Maria Francia M. Laxamana	Field Implementation and Coordination Team	Assitant Secretary of Health		
9	Asec. Elmer G. Punzalan	Field Implementation and Coordination Team (NCR and MMH)	Assitant Secretary of Health		
10	Asec. Nestor F. Santiago	Health Facilities and Infrastructure Development Team	Assitant Secretary of Health		

Department of Health

Swirex ng Kalusugan
001:2018 CERTIFIED

	High Level Forum on the Role of Health Technology Assessment (HTA) for Universal Health Care	VENUE:	The Sulu Riviera
	Health Technology Assessment (HTA)	DATE:	October 31, 2019

	OFFICE	DESIGNATION	EMAIL ADDRESS	CONTACT NO.	SIGNATURE
HTA BOARD MEMBERS					
Dr. C. Morales	Philippine Health Insurance Corporation (PHIC)	President and CEO			
H. Bello	PHIC	Philhealth Board Member			
Dr. R. Padua AFP (Ret.)	PHIC	Philhealth Board Member			
Dr. Niela G. Gonzaga	PHIC	BM, Expert Panel			
OFFICE OF SCIENCE AND TECHNOLOGY					
T. Dela Peña	Department of Science and Technology (DOST)	Secretary			
EXPERIMENTAL REPRESENTATIVE					
Helen Tan, MD	Committee on Health House of Representative	Chairperson			
ADDITIONAL RESOURCE PERSONS					
Dr. Atanador	Health Intervention and Technology Assessment	Founding Leader			



Department of Health

Kagawaran ng Kalusugan
ISO 9001:2008 CERTIFIED

ACTIVITY:	High Level Forum on the Role of Health Technology Assessment (HTA) for Universal Health Care	VENUE:	The Sulu Riviera
FACILITATOR:	Health Technology Assessment (HTA)	DATE:	October 31, 2019

	OFFICE	DESIGNATION	EMAIL ADDRESS	CONTACT NO.	SIGNATURE
18	Dr. Anthony Culyer	University of York	Professor Emeritus		
	Dr. Tessa Tan-Torres Edejer	World Health Organization	Coordinator, Economic Analysis and Evaluation		
20	Dr. Francis Ruiz	Imperial College of London			
21	Mr. Sven Engels	HITAP	Overseas Development Institute Fellow (Economist)		
22	Dr. Wanrudee Isaranuwachai	HITAP	Senior Researcher		W.I.
23	Ms. Waranya Rattanavipapong	HITAP	Head		23. A
	Ms. Alia Luz	HITAP	International Project Coordinator		
25	Ms. Benjarin Santatiwongchai	HITAP	Project Associate		
26	Ms. Apinya Mattaded	HITAP	Communication Officer		
27	Ms. Saudamini Vishwanath Dabak	HITAP	Technical Advisor		
28	Ms. Aparna Ananthakrishnan	HITAP	Overseas Development Institute Fellow		
29	Ms. Dianna Beatriz Bayani	Health Intervention and Technology Assessment Program (HITAP)	Researcher		



ACTIVITY:	High Level Forum on the Role of Health Technology Assessment (HTA) for Universal Health Care	VENUE:	The Sulu Riviera
FACILITATOR:	Health Technology Assessment (HTA)	DATE:	October 31, 2019

		OFFICE	DESIGNATION	EMAIL ADDRESS	CONTACT NO.	SIGNATURE
30	Ms. Carmela Barcelona	World Health Organization (WHO)	Consultant, Philippine Health Agenda			
31	Dr. Socorro Escalante	WHO	Technical Officer			
I. LOCAL RESOURCE PERSONS						
32	Dr. Rogelio Dazo, Jr.	Philippine Medical Association	Representative			
33	Dr. Marie Carmela Lapitag	National Institute of Health	Representative			
34	Mr. Raymond Villaroman	Pharmaceutical and Healthcare Association of the Philippines (PHAP)	Representative			
35	Ms. Fatima Lorenzo	Philippine Alliance of Patients Organization (PAPO)	President			
36	Mr. Bernardino Sayo	Union Local Authorities of the Philippines (ULAP)	President			
37	Ishia X. Z. Oruga	HOR COUN. A. TAN				
38	JACQUE LOU ESCANDOR	HOR COUN. A. TAN				
39	IRIS MONTES	COUN. A. TAN				
40						



ACTIVITY:	High Level Forum on the Role of Health Technology Assessment (HTA) for Universal Health Care	VENUE:	The Sulu Riviera
FACILITATOR:	Health Technology Assessment (HTA)	DATE:	October 31, 2019

	NAME	OFFICE	DESIGNATION	EMAIL ADDRESS	CONTACT NO.	SIGNATURE
C. Department of Science and Technology (DOST)						
1	Dr. Rowena Cristina L. Guevarra	DOST	Undersecretary			
2	Dr. Jaime C. Montoya	DOST	Director			<i>J. C. Montoya</i>
4	Mr. Vincent Tumlos	DOST	Representative			<i>V. Tumlos</i>
5	Ms. Irma P. Brul	DOST	Representative			<i>I. Brul</i>
6	Ms. Shienna Marie A. Pontillas	DOST	Representative			<i>S. Pontillas</i>
7	<i>Maria Elizabeth R. Gajigas</i>	DOST				<i>M. Gajigas</i>
8	<i>MARIC JOSE TANO</i>	DOST				<i>M. Tano</i>
9		DOST				
10		DOST				
D. Resource Persons						
11	Dr. Jose P. Santiago	Philippine Medical Association	President			
12	<i>Dr. Eva Maria C. Cutiongco-Dela Paz</i>	National Institute of Health	Executive Director			<i>E. Cutiongco</i>
13	Mr. Teodoro Padilla	Pharmaceutical and Healthcare Association of the Philippines (PHAP)	Executive Director			
14	<i>Einstein Rojas</i>	<i>TAPD</i>				<i>E. Rojas</i>



Department of Health
Kagawaran ng Kalusugan
ISO 9001:2008 CERTIFIED

ACTIVITY:	High Level Forum on the Role of Health Technology Assessment (HTA) for Universal Health Care	VENUE:	The Sulu Riviera
FACILITATOR:	Health Technology Assessment (HTA)	DATE:	October 31, 2019

	NAME	OFFICE	DESIGNATION	EMAIL ADDRESS	CONTACT NO.	SIGNATURE
15	Kara Alkपाल	PAPO				
16						
17						
18						
19						
20						
21						
22						
23						
24						
25						



Department of Health

Kagawaran ng Kalusugan
ISO 9001:2008 CERTIFIED

ACTIVITY:	High Level Forum on the Role of Health Technology Assessment (HTA) for Universal Health Care	VENUE:	The Sulu Riviera
FACILITATOR:	Health Technology Assessment (HTA)	DATE:	October 31, 2019

	OFFICE	DESIGNATION	EMAIL ADDRESS	CONTACT NO.	SIGNATURE
J. Professional Organizations, Institutional Partners and other Stakeholders					
1	Dr. Marita V. Reyes	University of the Philippines, Manila (UPM)	Representative		
2	Dr. Ma. Carmen Tolabing	UPM	Representative		
3	Dr. Cecilia Maramba-Lazarte	UPM	Representative		
4	Dr. Jacinto Blas Mantaring III	UPM	Representative		
5	Dr. Noel Juban	UPM	Representative		
6	Dr. Imelda Peña	UPM	Representative		
7	Dr. Mary Ann Castor	UPM	Representative		
8	Dr. Katherine Ann Reyes	UPM	Representative		
9	Prof. Luz Barbara Dones	UPM	Representative		
10	Dr. Raymond Sarmiento	UPM	Representative		
11	Dr. Iris Thiele Isip-Tan	UPM	Representative		
12	Dr. Josefina Tuazon	UPM	Representative		
13	Dr. Maria Carinnes A. Gonzales	University of Sto. Tomas (UST)	Representative		
14	Dr. Minerva Calimag	UST	Representative		



ACTIVITY:	High Level Forum on the Role of Health Technology Assessment (HTA) for Universal Health Care	VENUE:	Thé Sulu Riviera
FACILITATOR:	Health Technology Assessment (HTA)	DATE:	October 31, 2019








	OFFICE	DESIGNATION	EMAIL ADDRESS	CONTACT NO.	SIGNATURE
15	Prof. Aleli Kraft University of the Philippines Diliman (UPD)	Representative			
16	Dr. Jose Enrico Lazaro UPD	Representative			
17	Atty. Bu Castro Alliance of All Health Organizations of the Nation-Philippines	Representative			
18	Dr. Martha Cayad-An Mindanao Health Project	Representative			
19	Dr. Annabelle Borromeo Philippine Nurses Association	Representative			
20	Dr. Lizette Lopez Philippine Society of Endocrinology, Diabetes and Metabolism	Representative			
21	Dr. Nina Gloriani St. Lukes Medical Center	Representative			
22	Dr. Mediadora Sanil <i>THE MEDICAL CITY</i> St. Lukes Medical Center	Representative			
23	Prof. Maria Isabelita Rogado Arelano Graduate School of Nursing	Representative		bel	
24	Dr. Joan Cristine Lareza Ateneo School of Medicine and Public Health	Representative			
25	Ms. Agnette Peralta <i>Union of Health Workers</i> FLUW-Riceland (Philippines) Graduate School	Representative			
26	Dr. Marc James Delos Santos Philippine College of Radiology	Representative			



ACTIVITY:		High Level Forum on the Role of Health Technology Assessment (HTA) for Universal Health Care			VENUE:		The Sulu Riviera
FACILITATOR:		Health Technology Assessment (HTA)			DATE:		October 31, 2019
	NAME	OFFICE	DESIGNATION	EMAIL ADDRESS	CONTACT NO.	SIGNATURE	
27	Prof. Catherine Lee Ramos	De La Salle University	Representative				
28	Dr. Limuel Abrogena	Philippine Academy of Family Physicians	Representative				
29	Dr. Gemillano Aligui	University of the East - Ramon Magsaysay Memorial Medical Center, Inc.	Representative				
30	Dr. Isidro Sia	Integrative Medicine for Alternative Healthcare Systems Philippines	Representative			I C Sia	
31	Dr. Martin Camara	Philippine Institute of Traditional and Alternative Healthcare	Representative				
32	Ms. Rosal Gonzales	Health Policy and Development Bureau (HPDPB)	Representative				
33	Mr. Noel Palaypayon	Epidemiology Bureau					
34	Dr. Israel Pargas	Philippine Health Insurance Corporation (PHIC)					
35	Dr. Mary Antonette Remonte	PHIC					
36	Mr. Robbie Palce	PHIC					
37	Ms. Glenda Ortaliz	PHIC					
38	Dr. Mariella Castillo	United Nation's Children Fund	Representative				

Rolla P. ...

ACTIVITY:	High Level Forum on the Role of Health Technology Assessment (HTA) for Universal Health Care	VENUE:	The Sulu Riviera
ACILITATOR:	Health Technology Assessment (HTA)	DATE:	October 31, 2019

	OFFICE	DESIGNATION	EMAIL ADDRESS	CONTACT NO.	SIGNATURE
9	Mr. Mario Balibago	UNICEF	Representative		
0	Dr. Marimel Pagcatipunan	Philippine Infectious Disease Society of the Philippines	Representative		
1	Dr. Imelda Luna	PIDSP	Representative		
2	Dr. Jo-Anne de Castro	PIDSP	Representative		
3	Dr. Richard Jordias	Philippine Society of Maternal Fetal Medicine	Representative		
4	Dr. Mario Bernardino	Philippine Obstetrics and Gynecological Society	Representative		
5	Dr. Jodor Lime	Philippine Genaral Hospital	Representative		
6	Dr. Lalaine D. Arcangel	San Lazaro Hospital	Representative		
7	Dr. Hubert Lapuz	Philippine Hospital Association	Representative		
8	Dr. Ma. Asuncion Silvestre	Kalusugan ng Mag-Ina, Inc.	Representative		
9	Ms. Elena Felix	Association of Positive Women Advocates, Inc.	Representative		
0	Ms. Imelda Fernandez	Association of Positive Women Advocates, Inc.	Representative		
1	Mr. Joshua Young	AIDS Society of the Philippines	Representative		



ACTIVITY:	High Level Forum on the Role of Health Technology Assessment (HTA) for Universal Health Care	VENUE:	The Sulu Riviera
FACILITATOR:	Health Technology Assessment (HTA)	DATE:	October 31, 2019

	OFFICE	DESIGNATION	EMAIL ADDRESS	CONTACT NO.	SIGNATURE
K. Secretariat					
1	Ms. Alice C. Laquindanum	DOH-Pharmaceutical Division	Administrative Officer IV		<i>A. Laquindanum</i>
2	Mr. Mateo Celis, Jr.	HTA Unit	Administrative Assistant VI		<i>M. Celis</i>
3	Ms. Jovelyn Veranda	HTA Unit	Sr. Administrative Assistant III		<i>J. Veranda</i>
4	<i>Marife Leon</i>		<i>Executive Director</i>		<i>M. Leon</i>
5	<i>CHRIS MORALES</i>				<i>C. Morales</i>
6	<i>ZENaida DY REYNOLDS</i>				<i>Z. Reynolds</i>
7	<i>ERWIN DE MORA</i>	<i>PIRSDG</i>	<i>President</i>		<i>E. De Mora</i>
8	<i>JAN LLEVADO</i>	<i>DPCB</i>	<i>MO IV</i>		<i>J. Llevado</i>
9					
10					
11					
12					
13					
14					